NDAC Approach To OTC Switches Highlighted At Corticosteroid Meeting

A joint FDA advisory committee meeting evaluating the Rx-to-OTC switch prospects of topical corticosteroids underscored the different approaches to switches taken by OTC drug advisors and more cautious prescribers with category-specific expertise